Recommended

New webinar in 2025: Trends for life sciences quality leaders in 2025 – mastering what matters! Register your details now to secure your place!
New upcoming webinar: Navigating pharmaceutical environmental monitoring in a changing industry! Register your details today!
Explore our new Pharma Horizons: Sustainability report for key developments in the pharmaceutical industry!

List view / Grid view

News

six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol
six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol

Sanofi and Regeneron announce new results from six Phase 3 trials showing that alirocumab significantly reduced LDL cholesterol

19 November 2014 | By Sanofi / Regeneron Pharmaceuticals

Sanofi and Regeneron Pharmaceuticals, Inc. today announced new detailed positive results from six Phase 3 ODYSSEY trials that showed alirocumab significantly reduced low-density lipoprotein cholesterol (LDL-C, or "bad" cholesterol). Alirocumab is an investigational fully human monoclonal antibody targeting the protein PCSK9 (proprotein convertase subtilisin/kexin type 9) that is being evaluated…

Bioquell
Bioquell

Bioquell Pod study presented at the HIS Conference 2014

18 November 2014 | By Bioquell

Reducing infection transmission risk on a paediatric high dependency unit was just one of the topics under discussion at Lyon, France on the first day of the Healthcare Infection Society Conference 2014...

Pills
Pills

Entrenched misconceptions about antibiotics revealed in new survey

18 November 2014 | By Public Health England

Four in ten people take antibiotics for a cough or runny nose despite both conditions normally clearing up without treatment, according to new research out by Public Health England (PHE) for European Antibiotic Awareness Day (EAAD)...

Abbott logo
Abbott logo

New research in the international medical journal CHEST showed patients had reduced hospital stays, medical costs and returns to the hospital

18 November 2014 | By

People aged 65 and older, who were being treated for chronic obstructive pulmonary disease (COPD) in the hospital and received nutrition treatment (oral nutrition supplements) had reduced lengths of stay, hospital costs and chances of returning to the hospital within 30-days, according to a study published in CHEST...

Bristol Myers Squibb logo
Bristol Myers Squibb logo

Analyses from Phase IIIb Study provide additional data in earlier use of Orencia (abatacept) plus Methotrexate (MTX)

18 November 2014 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company announced results of several new sub-analyses of the Phase IIIb AVERT (Assessing Very Early Rheumatoid arthritis Treatment) trial that investigated the use of Orencia plus methotrexate (MTX) in biologic and MTX-naïve citrullinated protein (CCP)-positive early moderate to severe rheumatoid arthritis (RA) patients...

Probiodrug
Probiodrug

Probiodrug to present data on therapeutic concept of targeting pyro-Glu Abeta and its frontrunner QC-inhibitor PQ912 at International Alzheimer Conferences

17 November 2014 | By Probiodrug

Probiodrug AG, a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s Disease, announces that Prof. Hans-Ulrich Demuth, co- founder and consultant of Probiodrug, will be reviewing the target validation and summarize data on its lead product candidate PQ912 at two international conferences...

Moberg Pharma
Moberg Pharma

Moberg Pharma changes in Board of Directors

17 November 2014 | By Moberg Pharma

Moberg Pharma AB announces that George E. Aitken-Davies has resigned from the Board of Directors of Moberg Pharma in conjunction with the final earn-out payment related to the acquisition of Alterna LLC in 2012...

Bristol Myers Squibb logo
Bristol Myers Squibb logo

Study comparing Opdivo (nivolumab) to chemotherapy in treatment naïve advanced melanoma patients marks first PD-1 immune checkpoint inhibitor to demonstrate a survival benefit in a Phase 3 trial

17 November 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced results from CheckMate -066, a Phase 3 randomized double blind study, comparing Opdivo, an investigational PD-1 immune checkpoint inhibitor, to the chemotherapy dacarbazine (DTIC) in patients with treatment naïve BRAF wild-type advanced melanoma (n=418)...